Portfolio Finder

Abalos

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.

HTGF-Manager: Dr. Frank Hensel
Added to portfolio 10. Jul 2019

Emergence Therapeutics

Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat
Problem: Solid cancers are still very difficult to treat. Most treatments increase life expectancy, but only a few lead to a complete cure. Antibody drug conjugates (ADCs) have proven to be a promising therapeutic approach, but still cause significant and toxic side effects.

The solution: Emergence Therapeutics has identified several areas where ADCs can be improved. These are the antibody itself, the toxin used to kill the cancer cell, and the linker that couples the toxin to the antibody.

Technology/ IP: The antibody-related IP is in-licensed from the University of Aix-Marseille (France) and the toxin-related IP is in-licensed from Heidelberg Pharma.
The IP and all results generated for the ADC in development will be out-licensed or sold by Emergence.

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 26. Nov 2019

Immunservice

Immunservice GmbH develops biomimetic immune hormones, in particular interleukin-2, for safer, more effective and potentially curative therapies, especially in cancer.

HTGF-Manager: Ulrike Kalapis
Added to portfolio 20. Jul 2007

Invasight

Invasight is a Swiss-based early-clinical stage biotech start-up. Our breakthrough technology, ACINDA accelerates drug discovery and enables design of specific protein-protein interaction antagonists (PPIAs) for non-traditional intercellular protein targets, which cause cancer cell invasion. Our first-in-class PPIAs combine potent anti-tumour activity with a favourable safety profile for patients with invasive cancers. The most advanced of these first-in-class, protein-protein interaction antagonists is F2i, a inhibitor of pro-invasive FGFR signalling. F2i is currently in 'pre-clinical' validation stage of drug development.

HTGF-Manager: Dr. Julian Zachmann
Added to portfolio 20. Jul 2007

Tacalyx

Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility of synthesizing these complex structures allows the production of specific antibodies for the treatment of currently unsatisfactorily treatable cancers.

Website: tacalyx.com
HTGF-Manager: Dr. Lena Krzyzak
Added to portfolio 02. Jul 2019

Thermosome

Thermosome develops novel drugs for locally-advanced solid tumors by using nanocarriers for heat-induced local drug delivery and thereby reaches up to 15 fold higher local drug concentrations.

HTGF-Manager: Dr. Caroline Fichtner
Added to portfolio 15. Oct 2015

WMT

WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is based on the fact that many cancer cells predominantly produce their energy through a high rate of glycolysis followed by lactic acid fermentation even in the presence of abundant oxygen. Using this mechanism for the treatment of cancer turns out to be very difficult, as interventions targeted at the sugar metabolism also cause harm to healthy cells. The approach WMT is using offers an improved therapeutic window as opposed to classical cancer medicines.

HTGF-Manager: Dr. Martin Pfister
Added to portfolio 29. Apr 2021

Zimmer BioTech

As early as 2012, Zimmer contributed to the development of a drug based on the compound 5-Aminolevulinic acid for use in the treatment of actinic keratoses. The spin-off Zimmer BioTech has been active since October 2016 and is funded by Bonn-based High-Tech Gründerfonds, Germany’s largest seed stage investor. Currently the company is working on the approval of a 5-ALA based generic (ZimmerStick) in the US and develops the product “Alavin deep” for the treatment of acne.

Website: zimmer.de
HTGF-Manager: Dr. Frank Hensel
Added to portfolio 13. Jun 2017